Medical information Clinical review pending

Cytogenetics

Immunohistochemistry MDM2 Test

The Immunohistochemistry MDM2 Test detects MDM2 protein in tumor tissue, aiding in cancer diagnosis and treatment planning, particularly for soft tissue sarcomas and certain breast cancers. Confirm with the laboratory before booking.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Formalin-fixed, paraffin-embedded tumor tissue block or unstained slides from the biopsy site.
Results: Confirm with the laboratory before booking.
Preparation: No specific patient preparation is required. Ensure the laboratory receives the histopathology report and relevant clinical history.

Test priceKSh 7,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Immunohistochemistry MDM2 Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Diagnosis and classification of soft tissue sarcomas
✓Evaluation of certain types of breast cancer
✓Assessment of tumor aggressiveness
✓Guidance for treatment planning
✓Prognostic evaluation

In plain language

What this test helps you understand

This test helps assess the expression of the MDM2 protein in tumor tissue, which can provide valuable information about tumor aggressiveness and potential response to therapy in certain cancers, particularly soft tissue sarcomas and specific types of breast cancer.

The Immunohistochemistry MDM2 Test is a specialized diagnostic procedure used in oncology to detect the MDM2 protein in tumor tissues. Understanding the presence and levels of MDM2 is essential for assessing tumor behavior and guiding treatment decisions. This test measures the expression of the MDM2 protein, which can be overexpressed in certain cancers. Elevated levels may indicate a more aggressive tumor. This test is typically considered for patients with confirmed diagnoses of specific cancers, such as soft tissue sarcomas or certain breast cancers, or those with relevant symptoms or family history. Results are interpreted by pathologists and discussed with your oncologist to understand their implications for prognosis and treatment. DNA Labs Kenya offers this test with branches in major cities and home sample collection options.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationNo specific patient preparation is required. Ensure the laboratory receives the histopathology report and relevant clinical history.

SampleFormalin-fixed, paraffin-embedded tumor tissue block or unstained slides from the biopsy site.

MethodologyImmunohistochemistry (IHC) using specific antibodies to detect MDM2 protein expression in tissue sections.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

The test results must be interpreted in the context of the patient's clinical history, histopathology, and other diagnostic findings. The absence or presence of MDM2 protein expression alone is not diagnostic of cancer.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

MDM2 is a protein that plays a role in cell growth and division. Its overexpression is associated with certain types of cancer.

This test helps doctors understand the characteristics of a tumor, particularly in cases of soft tissue sarcomas and certain breast cancers, to guide diagnosis and treatment.

A positive result indicates the presence of MDM2 protein in the tumor tissue. The level of expression is assessed and interpreted by a pathologist in conjunction with clinical information.

Results are interpreted by a pathologist and discussed with your oncologist. The level of MDM2 expression can provide insights into tumor behavior and prognosis.

No specific patient preparation is required, but providing the histopathology report and clinical history is essential for accurate interpretation.

You can book the test by contacting DNA Labs Kenya via phone or WhatsApp at +254711564616 or visiting one of our branches.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp